Kenneth Newton, MD
Internal Medicine · Naugatuck, CTNPI 1194799700
Payments from drug & device makers
Across 213 payments — averaging $18.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boehringer Ingelheim$492
- AstraZeneca$483
- GSK$396
- Lilly USA, LLC$345
- Novo Nordisk$305
- Pfizer$235
- plus $2K from 25 others
What the payments were for
- Food & beverage$3,880100%
- Education$60%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boehringer Ingelheim | 25 | $492 |
| AstraZeneca | 33 | $483 |
| GSK | 24 | $396 |
| Lilly USA, LLC | 18 | $345 |
| Novo Nordisk | 14 | $305 |
| Pfizer | 13 | $235 |
| Johnson & Johnson | 15 | $228 |
| AbbVie(2 entities) | 10 | $192 |
| Merck | 11 | $184 |
| Amgen(2 entities) | 8 | $152 |
| Eisai Inc. | 7 | $122 |
| Sanofi-aventis U.S. LLC | 6 | $118 |
| Amarin Pharma, Inc. | 5 | $98 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 3 | $62 |
| Vanda Pharmaceuticals Inc. | 2 | $61 |
| Bayer | 2 | $49 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $42 |
| Biohaven Pharmaceuticals, Inc. | 1 | $33 |
| Kowa Pharmaceuticals America, Inc. | 2 | $31 |
| Vertex | 1 | $30 |
| Astellas Pharma US Inc | 1 | $29 |
| Avanir Pharmaceuticals, Inc. | 1 | $29 |
| Exact Sciences | 1 | $25 |
| Abbott | 1 | $24 |
| Inari Medical, Inc. | 1 | $22 |
| Intra-sana Laboratories | 1 | $20 |
| Dexcom, Inc. | 1 | $20 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $17 |
| Sanofi Pasteur Inc. | 1 | $16 |
| Novartis | 1 | $15 |
| Qiagen, LLC | 1 | $13 |
How this compares
$3,886 in reported general payments places this provider in the 85th percentile of 2,067 internal medicine providers in Connecticut.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 28 | $56,233 |
| EliquisApixaban | 34 | $46,852 |
| JanumetSitagliptin Phos/Metformin Hcl | 15 | $24,447 |
| JardianceEmpagliflozin | 13 | $23,033 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 39 | $22,346 |
| TrulicityDulaglutide | 14 | $19,388 |
| FarxigaDapagliflozin Propanediol | 15 | $18,898 |
| Breo ElliptaFluticasone/Vilanterol | 12 | $7,547 |
| Pantoprazole Sodium | 38 | $5,150 |
| Atorvastatin Calcium | 416 | $3,990 |
| Humulin 70/30 KwikpenInsulin Nph Hum/Reg Insulin Hm | 12 | $3,135 |
| Potassium Chloride | 21 | $2,628 |
| Rosuvastatin Calcium | 138 | $2,078 |
| Ezetimibe | 73 | $2,012 |
| Levothyroxine Sodium | 137 | $1,943 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $305 | $56,23328 claims |
| PfizerEliquis | $235 | $46,85234 claims |
| GSKAnoro Ellipta, Breo Ellipta | $396 | $29,89351 claims |
| MerckJanumet | $184 | $24,44715 claims |
| Boehringer IngelheimJardiance | $492 | $23,03313 claims |
| Lilly USA, LLCTrulicity | $345 | $19,38814 claims |
| AstraZenecaFarxiga | $483 | $18,89815 claims |
| AbbVieSynthroid | $192 | $1,00315 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 2,067 internal medicine providers in Connecticut.
Other internal medicine in Naugatuck
- Joseph SouferWaterbury$21.5M
- David RadinStamford$7M
- Steven RyderWestport$3.9M
- Nancy BrownNew Haven$2.8M
- Charles MontanoCromwell$2.8M
- Arthur DecillisMadison$1M
- Michelle MallitzTrumbull$971K
- Allen HellerWoodbridge$758K
- Gary BlickNorwalk$717K
- Margaret ChusteckaHamden$652K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.